DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations

- October 13th, 2016

VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 13, 2016 /PRNewswire/ — DelMar Pharmaceuticals (NASDAQ:DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company and its research collaborators have been invited to present data regarding the progress of VAL-083 at the following upcoming peer-reviewed scientific conferences:

VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 13, 2016 /PRNewswire/ — DelMar Pharmaceuticals (NASDAQ:DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company and its research collaborators have been invited to present data regarding the progress of VAL-083 at the following upcoming peer-reviewed scientific conferences:

  • European Association of NeuroOncology (EANO) Annual Meeting (Heidelberg, GermanyOct. 12 – 16, 2016);
  • AACR DNA Repair:  Tumor Development and Therapeutic Response (Montreal, CanadaNov. 2 – 5, 2016);
  • AACR New Horizons in Cancer Research:  Delivering Cures through Cancer Research (Shanghai, ChinaNov. 2 – 4, 2016);
  • Society for NeuroOncology Annual Meeting and CNS Anti-Cancer Drug Development Conference (Scottsdale, USANov. 16 – 20, 2016);
  • EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (Munich, GermanyNov 29Dec. 2, 2016); and
  • IASLC 17th World Congress on Lung Cancer (Vienna, AustriaDec. 4 – 7, 2016).

“We are pleased to accept these invitations to present new data at these prestigious peer-reviewed meetings,” said Jeffrey Bacha, DelMar’s chairman & CEO.  “Data presented at these global meetings will highlight the continued success of our strategy to leverage historical clinical validation from prior NCI-sponsored research with a modern understanding of VAL-083’s unique anti-cancer mechanism.”
VAL-083 is a “first-in-class,” small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments.
“Taken together, these data support VAL-083’s potential to address unmet medical needs in major cancer indications for patients whose tumors have failed, or exhibit features that make them resistant or unlikely to respond to, current standard-of-care chemotherapy,” added Mr. Bacha.
Connect with DelMar Pharmaceuticals (NASDAQ:DMPI) to receive an Investor Presentation.

Leave a Reply